Blog
RSS FeedPosted by Michael Wonder on 30 Jan 2026
Canadians wait too long for access to innovative drugs, cautions the MEI
29 January 2026 - Pharmaceutical innovation is responsible for up to 66% of the increase in the age of death ...
Posted by Michael Wonder on 19 Jan 2026
Early access to supposedly innovative medicines: for a more informed bet
19 December 2025 - The evaluation of early access requests for medicines inherently involves a degree of uncertainty. Indeed, it relies ...
Posted by Michael Wonder on 26 Nov 2025
Chinese pharma is on the cusp of going global
23 November 2025 - Its fast moving, cut price drugmakers stand to make more money abroad than at home. ...
Posted by Michael Wonder on 27 Oct 2025
Flaws in the FDA’s new priority voucher program
25 October 2025 - A new FDA program is being promoted as a tool to facilitate the development and approval of ...
Posted by Michael Wonder on 20 Sep 2025
A new era of dementia treatment is coming. We are not ready.
19 September 2025 - Inequality in accessing new drugs, the high cost of treatment, and underprepared hospital systems: these obstacles to ...
Posted by Michael Wonder on 03 Sep 2025
Australian scientists in hunt for cutting edge treatments, medicine
3 September 2025 - A mission to improve our notoriously slow medicine access system will seek innovations around the globe. ...
Posted by Michael Wonder on 04 Feb 2025
Comanche Biopharma awarded Innovation passport designation by the UK Innovative Licensing and Access Pathway Steering Group for CBP-4888, an investigational siRNA drug candidate for the treatment of sFlt1-mediated preterm pre-eclampsia
30 January 2025 - A novel investigational drug candidate, CBP-4888 leverages the precise targeting ability of siRNAs to downregulate sFlt1 ...
Posted by Michael Wonder on 28 Dec 2024
What price is society willing to pay for new drugs?
12 December 2024 - The purpose of England's NHS is to improve the health and wellbeing of the nation through provision ...
Posted by Michael Wonder on 13 Dec 2024
UK MHRA grants innovation passport designation to ILiAD Biotechnologies BPZE1 next generation intranasal pertussis vaccine
4 December 2024 - ILiAD Biotechnologies today announced that the UK MHRA has granted Innovation Passport designation to BPZE1, the leading ...
Posted by Michael Wonder on 07 Oct 2024
Crossing the equity chasm: addressing a second valley of death in biomedical innovation
3 October 2024 - Traditionally, the term valley of death refers to the gap where advancements in basic research fail to ...
Posted by Michael Wonder on 12 Jul 2024
Incorporating real option value in valuing innovation: a way forward
10 July 2024 - Considerable progress has been made in defining and measuring the real option value of medical technologies. ...
Posted by Michael Wonder on 20 Jun 2024
What good are whizzy new drugs if the world can’t afford them?
14 June 2024 - Bringing gene therapies and obesity drugs to the masses will require financial innovation too, says Steven Pearson. ...
Posted by Michael Wonder on 29 May 2024
KRPIA urges incoming Assembly to recognise new drugs’ value
28 May 2024 - The Korean Research based Pharma Industry Association (KRPIA) called for the 22nd National Assembly, which is ...
Posted by Michael Wonder on 24 May 2024
NICE and NHS England announce plan to enable innovative tech to be adopted quicker
23 May 2024 - NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies ...
Posted by Michael Wonder on 07 Mar 2024
Early impact of the Inflation Reduction Act on drug discovery
6 March 2024 - Despite the concerns of the biopharma industry, the Inflation Reduction Act has been enacted and with it, ...